sur Applied DNA Sciences, Inc.
Applied DNA Receives Notice of Allowance for Key U.S. Patent
STONY BROOK, NY / ACCESSWIRE / June 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced it received a Notice of Allowance from the USPTO for patent application 18/302,247, entitled "Compositions and Methods for RNA Synthesis."
The patent will cover the composition of the company's chemically modified RNA polymerase enzyme, branded Linea™ RNAP, until 2041. This enzyme is a core component of the Linea™ IVT platform, which enables more efficient mRNA production with reduced double-stranded RNA contamination. Applied DNA acquired the technology via its acquisition of Spindle Bio, Inc. in July 2023.
Dr. James A. Hayward, CEO of Applied DNA, highlighted the significance of this patent allowance in tandem with the company's advancing GMP capabilities. He noted the potential to capture market share amid the development of approximately 450 mRNA therapies globally, many in the preclinical stage.
R. H.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Applied DNA Sciences, Inc.